Product Candidate
Discovery
PRECLIN
PHASE 1
PHASE 2
PHASE 3
MARKET
Status
HCVProtease Inhibitor
glecaprevir-containing combo* (MAVYRET™)
Pan-genotypic: Marketed by AbbVie
HCVProtease Inhibitor
paritaprevir-containing regimens
GT1 and GT4: Marketed by AbbVie**
NASHFXR Agonist
EDP-305
Phase 2 "ARGON-1" study
PBCFXR Agonist
EDP-305
Phase 2 "INTREPID" study
RSVN-protein Inhibitor
EDP-938
Phase 2
HBVCore Assembly
Inhibitor
EDP-514
Preclinical
NASHFXR Agonist follow-on
Preclinical
NASHUndisclosed
Preclinical

*Fixed-dose combination, formerly known as G/P, contains glecaprevir and AbbVie's NS5A Inhibitor, pibrentasvir. Marketed ex U.S. as MAVIRET.
**VIEKIRA PAK and TECHNIVIE are no longer marketed in the U.S.; VIEKIRAX is still sold primarily in select jurisdictions where MAVYRET is not yet approved.